TARDBP and amyotrophic lateral sclerosis: In addition to tumour, AAV-Cas13d has also been delivered to specific tissues to knock down various targets and achieved phenotypic rescue in mouse models of age-related macular degeneration [23], hearing loss [25], Parkinson’s disease [22], TDP-43 proteinopathy [32] and amyotrophic lateral sclerosis (ALS) [33], respectively.